Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Source: View publication →
In high-risk patients with hypertension, treatment with an ACE inhibitor plus a calcium channel blocker (benazepril-amlodipine) was superior to an ACE inhibitor plus a thiazide diuretic (benazepril-hydrochlorothiazide) in reducing cardiovascular events, despite similar blood pressure control.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ACCOMPLISH trial provided landmark evidence that combination therapy with an ACE inhibitor and a calcium channel blocker is superior to an ACE inhibitor combined with a thiazide diuretic for reducing cardiovascular morbidity and mortality in high-risk patients. Crucially, it challenged the long-held dogma that all antihypertensive agents offer equal cardiovascular protection for a given degree of blood pressure reduction, demonstrating that the choice of specific add-on therapy dictates clinical outcomes.
Historical Context
Prior to the ACCOMPLISH trial, step-care approaches and guidelines (such as JNC 7) heavily favored starting with a thiazide diuretic, largely driven by the ALLHAT trial. ACCOMPLISH was the first large-scale, double-blind randomized trial to compare the clinical outcomes of two distinct fixed-dose combination antihypertensive regimens. Its profound results helped shift contemporary clinical practice guidelines, elevating ACE inhibitor/calcium channel blocker combinations as equally acceptable, and in many high-risk scenarios preferred, initial therapy over thiazide-centric regimens.
Guided Discussion
High-yield insights from every perspective
Why might combining an ACE inhibitor like benazepril with a dihydropyridine calcium channel blocker like amlodipine provide synergistic blood pressure control while simultaneously minimizing a specific common, dose-dependent side effect of the CCB?
Key Response
Dihydropyridine CCBs like amlodipine often cause peripheral edema due to preferential precapillary arteriolar vasodilation, which increases capillary hydrostatic pressure. ACE inhibitors cause postcapillary venodilation, helping to normalize this pressure gradient across the capillary bed and significantly reducing the incidence of amlodipine-induced peripheral edema.
Given the ACCOMPLISH trial findings, if you are initiating a high-risk patient with hypertension and type 2 diabetes on a two-drug regimen, why would you preferentially choose an ACEi/CCB combination over an ACEi/thiazide combination, and what specific metabolic parameters influence this choice?
Key Response
ACCOMPLISH demonstrated a 20% relative risk reduction in cardiovascular events with ACEi/CCB compared to ACEi/HCTZ. Beyond the CV event reduction, thiazide diuretics are known to cause adverse metabolic effects such as hypokalemia, hyperuricemia, and worsened glycemic and lipid profiles, which are particularly detrimental in high-risk patients like those with diabetes.
The ACCOMPLISH trial showed significant cardiovascular benefit with ACEi/CCB over ACEi/HCTZ despite similar peripheral blood pressure control. What central hemodynamic mechanisms and pleiotropic effects might explain this discrepancy in outcomes independent of brachial blood pressure?
Key Response
Amlodipine has been shown in studies (such as the CAFE substudy of the ASCOT trial) to lower central aortic blood pressure more effectively than thiazides or beta-blockers, even when peripheral brachial pressures are equivalent. Central blood pressure correlates more strongly with target organ damage and adverse CV events. Furthermore, amlodipine may have beneficial effects on endothelial function and arterial stiffness compared to HCTZ.
While ACCOMPLISH profoundly influenced combination therapy preferences, how do you reconcile its findings favoring amlodipine over HCTZ with the historical ALLHAT trial data, and how does this nuance influence how you teach trainees to select between a CCB and a diuretic?
Key Response
ALLHAT showed chlorthalidone was superior to amlodipine in preventing heart failure, whereas ACCOMPLISH showed ACEi/CCB was superior to ACEi/HCTZ for a composite CV endpoint. The vital teaching point is that drug choice within a class matters: HCTZ is less potent and shorter-acting than chlorthalidone. ACCOMPLISH compared amlodipine specifically against HCTZ, highlighting that if a diuretic strategy is chosen for high-risk patients, evidence-based, longer-acting thiazide-like diuretics (chlorthalidone or indapamide) should be preferred over HCTZ.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ACCOMPLISH trial was terminated early by the data and safety monitoring board due to clear evidence of benefit in the benazepril-amlodipine group. What are the statistical risks of stopping a trial early for efficacy, and how does this affect the point estimates of the treatment effect?
Key Response
Stopping trials early for benefit carries the risk of overestimating the true treatment effect, a phenomenon known as random high or truncation bias. Because trials are continuously monitored, stopping rules might be triggered at a peak in the fluctuating trajectory of accumulating data. Researchers must apply stringent stopping boundaries (e.g., O'Brien-Fleming) and consider using Bayesian shrinkage or penalized likelihood approaches to adjust these point estimates for future meta-analyses.
As a statistical reviewer evaluating the ACCOMPLISH manuscript, what critical concerns would you raise regarding the choice of hydrochlorothiazide at 12.5 to 25 mg daily as the active comparator, and how does this potential 'straw man' affect the trial's internal validity?
Key Response
A critical reviewer would flag that HCTZ at 12.5-25 mg has a short half-life and does not provide robust 24-hour blood pressure coverage, especially during the nighttime, compared to amlodipine 10 mg. Using a suboptimal diuretic dose as the comparator might exaggerate the benefit of the amlodipine arm, introducing a threat to construct validity by comparing a potent, long-acting agent against a weaker, shorter-acting one.
Based on the ACCOMPLISH trial results, how do current clinical practice guidelines (such as the 2017 ACC/AHA Hypertension guidelines) recommend initial combination therapy for stage 2 hypertension, and how did this trial shift the paradigm regarding the obligatory use of thiazide diuretics?
Key Response
The 2017 ACC/AHA guidelines recommend initiation of therapy with two first-line agents of different classes for stage 2 hypertension. ACCOMPLISH provides Level A evidence that combining a renin-angiotensin system inhibitor with a CCB is preferable to combining it with a thiazide diuretic in high-risk patients. This shifted the paradigm away from JNC-7's recommendation which heavily favored thiazide-based regimens for nearly all patients, establishing ACEi/CCB as a preferred initial combination.
Clinical Landscape
Noteworthy Related Trials
ALLHAT Trial
Tested
Chlorthalidone, amlodipine, or lisinopril
Population
Hypertensive patients aged 55 or older with at least one other CHD risk factor
Comparator
Comparison among the three active antihypertensive agents
Endpoint
Combined fatal coronary heart disease or nonfatal myocardial infarction
VALUE Trial
Tested
Valsartan-based regimen
Population
Hypertensive patients at high cardiovascular risk
Comparator
Amlodipine-based regimen
Endpoint
Composite of cardiac mortality and morbidity
ASCOT-BPLA Trial
Tested
Amlodipine with or without perindopril
Population
Hypertensive patients with at least three other cardiovascular risk factors
Comparator
Atenolol with or without bendroflumethiazide
Endpoint
Non-fatal myocardial infarction and fatal coronary heart disease
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis